You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博雅生物(300294.SZ):與GC簽署戰略合作框架協議

格隆匯7月17日丨博雅生物(300294.SZ)公佈,為進一步加強各領域的交流與合作,共創發展契機,實現共贏、共同發展的目標,根據業務發展需要,公司與華潤醫藥集團有限公司(簡稱華潤醫藥)於2024年7月17日和GC Corp.(簡稱GC,“甲方”)簽署《戰略合作框架協議》。

戰略合作業務包括:

1、綠十字(中國)生物製品有限公司業務整合:雙方已簽署關於綠十字香港控股有限公司(“綠十字香港”)的股權協議,甲乙雙方將根據相關協議約定保障股權交割前的綠十字香港及其子公司的經營穩定及控制權的平穩過渡。

2、藥品進出口銷售:基於目前甲方關聯公司與綠十字香港的子公司安徽格林克醫藥銷售有限公司已重新簽署產品經銷協議,甲方將盡商業上的合理努力督促關聯公司履行產品經銷協議,乙方也將督促安徽格林克嚴格履行產品經銷協議。雙方建立藥品進出口銷售的戰略合作伙伴關係,甲方可依託乙方在中國市場開展臨牀研究、註冊申報及市場銷售渠道等方面的優勢,共同合作推動甲方創新產品在中國的上市銷售,乙方可依託甲方在韓國市場的領先地位,推動乙方及其關聯方產品在韓國上市銷售,以實現共贏。

3、產品技術合作:雙方將攜手開展血液製品、疫苗、細胞與基因治療和診斷業務等領域產品技術引進合作,通過技術許可、聯合研發、技術轉移、通過CDMO模式拓展海外業務等多種形式,共同推動產品技術創新與升級,實現技術成果的市場化應用與雙方業務的共贏發展。

4、在上述範圍之外,雙方可根據合作情況友好協商進一步拓展合作領域。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account